Allogeneic blood transfusion and cancer recurrence: 20 years later

Transfusion

Volumn 54, Issue 9, 2014, Pages 2149-2153

  Vamvakas, Eleftherios C ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN 3;

ALLOGENEIC BLOOD TRANSFUSION; BIOCHEMICAL RECURRENCE FREE SURVIVAL; BLOOD TRANSFUSION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CHARLSON COMORBIDITY INDEX; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; DOWN REGULATION; ERYTHROCYTE; GLEASON SCORE; HUMAN; IMMUNE RESPONSE; LEUKOCYTE; OVERALL SURVIVAL; PROSTATE CANCER; RECURRENCE RISK; REVIEW; DRUG EFFECTS; MALE; METABOLISM; PROCEDURES; PROSTATECTOMY; PROSTATIC NEOPLASMS; THROMBOCYTE;

APOLIPOPROTEIN A-I; BLOOD PLATELETS; BLOOD TRANSFUSION; HUMANS; LIPOPROTEINS, HDL3; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84908128602     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12689     Document Type: Review

References (40)

1. Gantt CL. Red blood cells for cancer patients. Lancet 1981; ii:363.
2. Vamvakas E. Perioperative blood transfusion and cancer recurrence: meta-analysis for explanation. Transfusion 1995;35:760-8.
3. Brand A, Houbiers JG. Clinical studies of blood transfusion and cancer. In: Vamvakas EC, Blajchman MA, editors. Immunomodulatory effects of blood transfusion. Bethesda (MD): American Association of Blood Banks Press; 1999. p. 145-90.
4. Ness PM, Walsh PC, Zahurak M, et al. Prostate cancer recurrence in radical surgery patients receiving autologous or homologous blood. Transfusion 1993;33:31-6.
5. Busch OR, Hop WC, Hoynck van Papendrecht MA, et al. Blood transfusion and prognosis in colorectal cancer. N Engl J Med 1993;328:1372-6.
6. Heiss MM, Mempel W, Delanoff CH, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous vs allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994;12: 1859-67.
7. Houbiers JG, Brand A, van de Watering LM, et al. A randomized controlled trial comparing the prognosis of colorectal cancer patients transfused with either leukocytedepleted or buffy coat-depleted blood. Lancet 1994;344: 573-8.
8. Vamvakas EC. Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion 1996;36:175-86.
9. McAlister FA, Clark HD, Wells PS, et al. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: a meta-analysis of unconfounded studies. Br J Surg 1998;85:171-8.
10. Jung S, Schluesener JH. Human T-lymphocytes recognize a peptide of single point-mutated oncogenic ras proteins. J Exp Med 1991;173:273-6.
11. Houbiers JG, Nijman HW, van der Burg SH, et al. In-vitro induction of human cytotoxic T-lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993;23:2072-7.
12. Smith ME, Marsh SG, Bodmer JG, et al. Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia. Proc Natl Acad Sci U S A 1989;86:5557-61.
13. Möller P, Momburg F, Koretz K, et al. Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res 1991;51: 729-36.
14. Bontkes HJ, Walboomers JM, Meijer JL, et al. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet 1988;351: 187-8.
15. Lange MM, van Hilten JA, van de Watering LM, et al. Leucocyte depletion of perioperative blood transfusion does not affect long-term survival and recurrence in patients with gastrointestinal cancer. Br J Surg 2009;96:734-40.
16. Bishara S, Adshead J. Re: Linder BJ, Frank I, Cheville JC et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy (Eur Urol 2013;63:839-45). Eur Urol 2013;64:e48.
17. Linder BJ, Frank I, Cheville JC, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol 2013;63: 839-45.
18. Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg 2012;256:335-44.
19. Liu L, Wang Z, Jiang S, et al. Perioperative allogeneic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a meta-analysis. PloS One 2013; 8:e64261.
20. Vamvakas EC, Moore SB. Perioperative blood transfusion and colorectal cancer recurrence: a qualitative statistical overview and meta-analysis. Transfusion 1993;33:754-65.
21. Yeoh TZ, Scavonetto F, Weingarten TN, et al. Perioperative allogeneic nonleukoreduced blood transfusion and prostate cancer outcomes after radical prostatectomy. Transfusion 2014;54:2175-81.
22. Chalfin HJ, Frank SM, Feng Z, et al. Allogeneic versus autologous blood transfusion and survival after radical prostatectomy. Transfusion 2014;54:2168-74.
23. Heal JM, Chuang C, Blumberg N. Perioperative blood transfusions and prostate cancer recurrence and survival. Am J Surg 1988;156:374-80.
24. McClinton S, Moffat LE, Scott S, et al. Blood transfusions and survival following surgery for prostatic carcinoma. Br J Surg 1990;77:140-2.
25. Davies AH, Ramarakha P, Cranston D, et al. Effect of blood transfusion on survival after radiotherapy as treatment for carcinoma of the prostate. Ann R Coll Surg Engl 1991;73: 116-8.
26. Eickhof JH, Göte H, Baeck J. Perioperative blood transfusion in relation to tumor recurrence and death after surgery for prostatic cancer. Br J Urol 1991;68:608-11.
27. Velagapudi SR, Frydenberg M, Oesterling JE, et al. Homologous blood transfusion in patients with prostate cancer: no effect on tumor progression or survival. Urology 1994;43: 821-7.
28. Paul R, Schmid R, Busch R, et al. Influence of blood transfusions during radical retropubic prostatectomy on disease outcome. Urology 2006;67:137-41.
29. Ford BS, Sharma S, Rezaishiraz H, et al. Effect of perioperative blood transfusion on prostate cancer recurrence. Urol Oncol 2008;26:364-7.
30. Bar-Yosef S, Melamed R, Page GG, et al. Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology 2001;94:1066-73.
31. Guzzo TH, Dluzniewski P, Orosco R, et al. Prediction of mortality after radical prostatectomy by Charlson cormorbidity index. Urology 2010;76:553-7.
32. Morgan TM, Barocas DA, Chang SS, et al. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol 2013;31:871-7.
33. Vamvakas E. Possible mechanisms of allogeneic blood transfusion-associated postoperative infection. Transfus Med Rev 2002;16:144-60.
34. Vamvakas E. Meta-analysis of randomized controlled trials comparing the risk of postoperative infection between recipients of allogeneic and autologous blood transfusion. Vox Sang 2002;83:339-46.
35. Thurer RL, Luban NL, AuBuchon JP, et al. Universal WBC reduction. Transfusion 2000;40:751-2.
36. Bordin JO, Blajchman MA. Blood transfusion and tumor growth in animal models. In: Vamvakas EC, Blajchman MA, editors. Immunomodulatory effects of allogeneic blood transfusion. Bethesda (MD): American Association of Blood Banks Press; 1999. p. 29-42.
37. Bordin JO, Bardossy L, Blajchman MA. Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of timing of the leukodepletion. Blood 1994;84:344-8.
38. Blajchman MA, Bardossy I, Carmen R, et al. Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood 1993;81:1880-82.
39. Clark DA, Gorczynski RM, Blajchman MA. Transfusionrelated immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecules and alloantigen. Transfusion 2008;48:214-21.
40. Lowry WS, Clark DA, Hanneman JH. Skin cancer and immunosuppression. Lancet 1973;i:1290-1.